Endogenous and synthetic agonists of GPR119 differ in signaling pathways and their effects on insulin secretion in MIN6c4 insulinoma cells.

Ning, Y, O'Neill, K, Lan, H, Pang, L, Shan, L.X., Hawes B.E., Hedrick, J.A.
Journal   Br J Pharmacol.
Species  
Analytes Measured   Insulin
Matrix Tested   MIN6c4 cell culture supernatants
Year   2008
Volume   155
Page Numbers   1056-65
Application   Metabolic
Abstract
BACKGROUND AND PURPOSE: GPR119 is a G protein-coupled receptor that is preferentially expressed in islet cells and mediates insulin secretion. Oleoyl-lysophosphatidylcholine and oleoylethanolamide (OEA) act as endogenous ligands for this receptor, whereas PSN375963 and PSN632408 are two recently reported synthetic agonists. In this study, we explored mechanisms underlying GPR119-induced insulin secretion. In addition, we assessed the potential utility of the synthetic agonists as tools for exploring GPR119 biology. EXPERIMENTAL APPROACH: We examined natural and synthetic GPR119 agonist activity at GPR119 in MIN6c4 and RINm5f insulinoma cells. We evaluated insulin secretion, intracellular calcium [Ca(2+)](i), ion channel involvement and levels of cAMP. KEY

RESULTS: We report that increases in insulin secretion induced by OEA were associated with increased cAMP and a potentiation of glucose-stimulated increases in [Ca(2+)](i). We also demonstrate that ATP-sensitive K(+) and voltage-dependent calcium channels were required for GPR119-mediated increases in glucose-stimulated insulin secretion. In contrast to OEA, the synthetic GPR119 agonist PSN375963 and PSN632408 have divergent effects on insulin secretion, cAMP and intracellular calcium in MIN6c4 cells. CONCLUSIONS AND IMPLICATIONS: The endogenous ligand OEA signals through GPR119 in a manner similar to glucagon-like peptide-1 (GLP-1) and its receptor with respect to insulin secretion, [Ca(2+)](i) and cAMP. In addition, PSN375963 and PSN632408 substantially differ from OEA and from one another. These studies suggest that the commercially available synthetic agonists, although they do activate GPR119, may also activate GPR119-independent pathways and are thus unsuitable as GPR119-specific pharmacological tools.

View Publications

Related Products

U-PLEX Custom Metabolic Group 1 (hu) Assays
BAFF, BDNF, β-NGF, C-Peptide, CTACK, ENA-78, Eotaxin, Eotaxin-2, Eotaxin-3, EPO, FGF-21, FGF-23, FLT3L, Fractalkine, FSH, G-CSF, Ghrelin (active), Ghrelin (total), GIP (active), GIP (inactive), GIP (total), GLP-1 (active), GLP-1 (inactive), GLP-1 (total), Glucagon, GM-CSF, GRO-α, I-309, IFN-α2a, IFN-β, IFN-γ, IL-1α, IL-1β, IL-1RA, IL-2, IL-2Rα, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12/IL-23p40, IL-12p70, IL-13, IL-15, IL-16, IL-17A, IL-17A/F, IL-17C, IL-17D, IL-17E/IL-25, IL-17F, IL-18, IL-21, IL-22, IL-23, IL-27, IL-29/IFN-λ1, IL-31, IL-33, Insulin, IP-10, Leptin, Luteinizing Hormone (LH), MCP-1, MCP-2, MCP-4, M-CSF, MDC, MIF, MIP-1α, MIP-5, PP, Proinsulin, PYY (total), SDF-1α, TARC, TNF-α, TNF-β, TPO, TRAIL, TSLP, VEGF-A, YKL-40 | Human
Multiplex
U-PLEX Metabolic Group 1 (hu) Assays
BAFF, BDNF, β-NGF, C-Peptide, CTACK, ENA-78, Eotaxin, Eotaxin-2, Eotaxin-3, EPO, FGF-21, FGF-23, FLT3L, Fractalkine, FSH, G-CSF, Ghrelin (active), Ghrelin (total), GIP (active), GIP (inactive), GIP (total), GLP-1 (active), GLP-1 (inactive), GLP-1 (total), Glucagon, GM-CSF, GRO-α, I-309, IFN-α2a, IFN-β, IFN-γ, IL-1α, IL-1β, IL-1RA, IL-2, IL-2Rα, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12/IL-23p40, IL-12p70, IL-13, IL-15, IL-16, IL-17A, IL-17A/F, IL-17C, IL-17D, IL-17E/IL-25, IL-17F, IL-18, IL-21, IL-22, IL-23, IL-27, IL-29/IFN-λ1, IL-31, IL-33, Insulin, IP-10, Leptin, Luteinizing Hormone (LH), MCP-1, MCP-2, MCP-4, M-CSF, MDC, MIF, MIP-1α, MIP-5, PP, Proinsulin, PYY (total), SDF-1α, TARC, TNF-α, TNF-β, TPO, TRAIL, TSLP, VEGF-A, YKL-40 | Human
U-PLEX Adipokine Combo 1 (hu)
BDNF, β-NGF, IL-1β, IL-6, IL-8, IL-10, Insulin, Leptin, MCP-1, TNF-α | Human
Multiplex
U-PLEX Diabetes Combo 1 (hu)
C-Peptide, GIP (total), GLP-1 (total), Glucagon, Insulin, Leptin, PYY (total) | Human
Multiplex
U-PLEX Diabetes Combo 2 (hu)
C-Peptide, GIP (total), GLP-1 (active), Glucagon, Insulin, Leptin, PYY (total) | Human
Multiplex
U-PLEX Human Insulin Assay
Insulin | Human
Singleplex
U-PLEX Metabolic Combo 1 (hu)
BAFF, BDNF, β-NGF, C-Peptide, FGF-21, FGF-23, FSH, Ghrelin (active), Ghrelin (total), GIP (active), GIP (inactive), GIP (total), GLP-1 (active), GLP-1 (inactive), GLP-1 (total), Glucagon, Insulin, Leptin, Luteinizing Hormone (LH), PP, Proinsulin, PYY (total) | Human
Multiplex
U-PLEX Obesity Combo 2 (hu)
C-Peptide, FGF-23, Ghrelin (total), GLP-1 (total), Insulin, Leptin, PYY (total) | Human
Multiplex
U-PLEX Human Insulin Antibody Set
Insulin | Human
R-PLEX Insulin Antibody Set
Insulin | Human
Singleplex
Human Active GLP-1(7-36)amide, Insulin, Glucagon, Leptin Kit
GLP-1 (active), Glucagon, Insulin, Leptin | Human
Multiplex
Human Active GLP-1, Insulin, Glucagon, Leptin Kit
GLP-1 (active), Glucagon, Insulin, Leptin | Human
Multiplex
Human GLP-1(7-36)amide, Glucagon, Insulin Kit
GLP-1 (active), Glucagon, Insulin | Human
Multiplex
Human Leptin, Insulin Kit
Insulin, Leptin | Human
Multiplex
Mouse/Rat Insulin, Glucagon Kit
Glucagon, Insulin | Mouse, Rat
Multiplex
Mouse Metabolic Kit
Insulin, Leptin | Mouse
Multiplex
Mouse/Rat GLP-1 (7-36)amide, Glucagon, Insulin Kit
GLP-1 (total), Glucagon, Insulin | Mouse, Rat
Multiplex
Mouse/Rat Insulin Kit
Insulin | Mouse, Rat
Singleplex
Mouse/Rat Active GLP-1 (7-36)amide, Insulin, Glucagon Kit
GLP-1 (total), Glucagon, Insulin | Mouse, Rat
Multiplex
Mouse/Rat Total Active GLP-1, Insulin, Glucagon Kit
GLP-1 (total), Glucagon, Insulin | Mouse, Rat
Multiplex
Human Insulin Kit
Insulin | Human
Singleplex
Rat Leptin, Insulin Kit
Insulin, Leptin | Rat
Multiplex
Browse Our Products

By Analytes
By Applications
Search
Customer Service/Orders


Scientific/Technical Support


Instrument Support


Company Headquarters